T
Transcend Therapeutics
Developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access
About Transcend Therapeutics
Transcend Therapeutics is a biotechnology company that is revolutionizing the way people treat neuropsychiatric illnesses. Their mission is to discover, develop, and deliver the next generation of psychoactive compounds, with the goal of providing better access to treatments for those suffering from mental illnesses.
Read full description
The team at Transcend Therapeutics is comprised of experienced professionals, including the first scientist to receive federal funding for clinical psychedelic research in 54 years and a drug development executive with pivotal contributions to 9 FDA approvals.
What makes Transcend Therapeutics stand out from other businesses in the same industry is their focus on compounds with clinical and nonclinical safety profiles in the public domain, as well as treatments with benefits over classic psychedelics. These benefits include the ability to administer while patients are on traditional antidepressants, a short treatment duration, minimal patient inebriation, and lack of undesirable subjective effects.
Transcend Therapeutics is driven by the goal of reducing the global economic burden of mental illness, which is estimated to reach $6 trillion by 2030. By providing better treatments and access to those suffering from mental illnesses, they aim to make a positive impact on the world.
At a glance
- Status
- Acquired
- Founded
- 2021
- Headquarters
- New York City, United States
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 85.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Psychology, Biotechnology, Drug Development, Health and Wellness, Medical & Healthcare, Neurology, Mental Health, Spinout, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2026 | $700M | $700M | Otsuka Pharmaceutical | ↗ |
| SERIES A✓Equity / VC | Feb 2023 | $40M | $160M | Global Founders Capital · Alpha Wave Global · Emerald Development Managers · Integrated | ↗ |
Growth signals
Latest recorded traffic for Transcend Therapeutics is 3.5K monthly website visits, down 54.5% over the last three months. Transcend Therapeutics's team grew 20.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
FJ Labs
AlleyCorp
Alpha Wave Global
Integrated
Series A2 investors entered at this stage
Global Founders Capital
Emerald Development Managers
Other known investors3 additional known investors
Otsuka Pharmaceutical
Yale University
Alumni Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Transcend Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Transcend Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.